Outcomes of severe uveitic glaucoma treated with Baerveldt implant: can blindness be prevented?
Annelie N TanMichiel F CornelissenCarroll A B WebersRoel J ErckensTos T J M BerendschotHenny J M BeckersPublished in: Acta ophthalmologica (2017)
The BGI is an effective and safe treatment for patients with refractive secondary glaucoma due to uveitis. In a majority of patients, VA remains stable and a low and stable IOP is maintained over time with an acceptable number of complications. In particular, patients with viral uveitis and glaucoma should be closely monitored for IOP peaks that may occur during episodes of a flare-up of uveitis, whereas at the other end of the spectrum, patients with JIA seem much more prone to hypotony maculopathy.
Keyphrases
- juvenile idiopathic arthritis
- ankylosing spondylitis
- end stage renal disease
- newly diagnosed
- optic nerve
- cataract surgery
- ejection fraction
- chronic kidney disease
- sars cov
- peritoneal dialysis
- prognostic factors
- disease activity
- early onset
- type diabetes
- risk factors
- patient reported outcomes
- adipose tissue
- rheumatoid arthritis
- systemic lupus erythematosus
- skeletal muscle
- combination therapy